Finance

Lists
CRMD:NASDAQ
CorMedix Inc
7,39 US$
0,00%
(0,00) 1D
7,39 US$
0,00% (0,00)
After hours
Closed: 14 ოქტ, 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CRMD...
Open
7,36 US$
High
7,53 US$
Low
7,27 US$
Mkt. cap
576,01 მლნ.
Avg. vol.
937,69 ათ.
Volume
1,12 მლნ.
P/E ratio
3,47
52-wk high
13,02 US$
52-wk low
6,12 US$
EPS
2,13 US$
Beta
1,40
Shares outstanding
77,94 მლნ.
No. of employees
191
Open
7,36 US$
High
7,53 US$
Low
7,27 US$
Mkt. cap
576,01 მლნ.
Avg. vol.
937,69 ათ.
Volume
1,12 მლნ.
P/E ratio
3,47
52-wk high
13,02 US$
52-wk low
6,12 US$
EPS
2,13 US$
Beta
1,40
Shares outstanding
77,94 მლნ.
No. of employees
191
News stories
From web sources and news partners
About CorMedix Inc
CEO-
Employees191
Founded2006
HeadquartersBerkeley Heights, ნიუ-ჯერსი, ამერიკის შეერთებული შტატები
SectorPharmaceutical industry
Analyst ratings
Based on 4 analysts giving stock ratings to CRMD in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for CRMD in the last 3 months.
Highest
Current 7,39 US$
15,00 US$ (+102,98%)
Average
14,25 US$ (+92,83%)
Lowest
13,00 US$ (+75,91%)
Analyst
Recommendation
Action
Price target
Projected
Date
Leonid Timashev
RBC Capital
Buy
Maintained
14,00 US$
+89,4%
10/08/2026
Unknown Analyst
Oppenheimer
Buy
Initiated
15,00 US$
+103%
09/23/2026
Brandon Folkes
H.C. Wainwright
Buy
Reiterated
13,00 US$
+75,9%
08/14/2026
Serge Belanger
Needham
Buy
Maintained
15,00 US$
+103%
08/13/2026
Roanna Ruiz
Leerink Partners
Buy
Reiterated
15,00 US$
+103%
05/15/2026
Les Sulewski
Truist Financial
Buy
Maintained
-
-
05/15/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
104,28 მლნ.
128,62 მლნ.
127,43 მლნ.
101,93 მლნ.
Cost of goods sold
7,57 მლნ.
11,17 მლნ.
12,00 მლნ.
14,50 მლნ.
Cost of revenue
7,57 მლნ.
11,17 მლნ.
12,00 მლნ.
14,50 მლნ.
Research and development expenses
5,10 მლნ.
8,60 მლნ.
7,21 მლნ.
6,68 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
36,64 მლნ.
29,38 მლნ.
34,25 მლნ.
27,53 მლნ.
Operating expense
45,36 მლნ.
48,12 მლნ.
51,76 მლნ.
44,52 მლნ.
Total operating expenses
52,93 მლნ.
59,29 მლნ.
63,77 მლნ.
59,02 მლნ.
Operating income
51,35 მლნ.
69,33 მლნ.
63,66 მლნ.
42,91 მლნ.
Other non operating income
-
-
-268,00 ათ.
-71,00 ათ.
EBT including unusual items
52,58 მლნ.
56,45 მლნ.
55,64 მლნ.
38,73 მლნ.
EBT excluding unusual items
51,89 მლნ.
68,47 მლნ.
63,39 მლნ.
42,84 მლნ.
Income tax expense
-55,99 მლნ.
42,43 მლნ.
17,04 მლნ.
12,74 მლნ.
Effective tax rate
-106,49%
75,16%
30,63%
32,90%
Other operating expenses
-
-
-
-
Net income
108,56 მლნ.
14,02 მლნ.
38,60 მლნ.
25,99 მლნ.
Net profit margin
104,11%
10,90%
30,29%
25,50%
Earnings per share
1,41
0,16
0,35
-
Interest and investment income
1,56 მლნ.
889,98 ათ.
-
-
Interest expense
-948,24 ათ.
-1,82 მლნ.
-
-
Net interest expenses
612,03 ათ.
-927,10 ათ.
-
-
Depreciation and amortization charges
-
-
-
-
EBITDA
55,14 მლნ.
79,76 მლნ.
74,20 მლნ.
53,45 მლნ.
Gain or loss from assets sale
-
-86,00 ათ.
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google აპები